DK36492D0 - Praeparat - Google Patents

Praeparat

Info

Publication number
DK36492D0
DK36492D0 DK92364A DK36492A DK36492D0 DK 36492 D0 DK36492 D0 DK 36492D0 DK 92364 A DK92364 A DK 92364A DK 36492 A DK36492 A DK 36492A DK 36492 D0 DK36492 D0 DK 36492D0
Authority
DK
Denmark
Prior art keywords
preparation
Prior art date
Application number
DK92364A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority to DK92364A priority Critical patent/DK36492D0/da
Publication of DK36492D0 publication Critical patent/DK36492D0/da
Priority to JP5516181A priority patent/JPH07504669A/ja
Priority to PCT/DK1993/000098 priority patent/WO1993018785A1/en
Priority to AU38887/93A priority patent/AU3888793A/en
Priority to EP93907819A priority patent/EP0631504A1/en
Priority to KR1019940703281A priority patent/KR950700754A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK92364A 1992-03-19 1992-03-19 Praeparat DK36492D0 (da)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DK92364A DK36492D0 (da) 1992-03-19 1992-03-19 Praeparat
JP5516181A JPH07504669A (ja) 1992-03-19 1993-03-18 新規薬剤
PCT/DK1993/000098 WO1993018785A1 (en) 1992-03-19 1993-03-18 Novel medicament
AU38887/93A AU3888793A (en) 1992-03-19 1993-03-18 Novel medicament
EP93907819A EP0631504A1 (en) 1992-03-19 1993-03-18 Novel medicament
KR1019940703281A KR950700754A (ko) 1992-03-19 1994-09-17 신규의 약물(novel medicament)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK92364A DK36492D0 (da) 1992-03-19 1992-03-19 Praeparat

Publications (1)

Publication Number Publication Date
DK36492D0 true DK36492D0 (da) 1992-03-19

Family

ID=8092684

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92364A DK36492D0 (da) 1992-03-19 1992-03-19 Praeparat

Country Status (6)

Country Link
EP (1) EP0631504A1 (da)
JP (1) JPH07504669A (da)
KR (1) KR950700754A (da)
AU (1) AU3888793A (da)
DK (1) DK36492D0 (da)
WO (1) WO1993018785A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
SK155694A3 (en) * 1992-06-15 1995-05-10 Pfizer Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
DE19530865A1 (de) * 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
CA2312190A1 (en) 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO1999043706A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1840134B1 (en) 1998-02-27 2016-04-13 Novo Nordisk A/S GLP-1 derivatives
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
HUP0103369A3 (en) * 1998-08-28 2002-03-28 Lilly Co Eli Use of insulinotropic peptides
EP1666054A1 (en) * 1998-08-28 2006-06-07 Eli Lilly & Company Method for administering insulinotropic peptides
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
CA2358107C (en) * 1998-12-22 2011-08-23 Eli Lilly And Company Shelf-stable formulation of glucagon-like peptide-1
AU2353701A (en) * 2000-01-11 2001-07-24 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
DE60114996T2 (de) 2000-03-08 2006-08-10 Novo Nordisk A/S Senkung des serum cholesterols
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2004105790A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
PT1687019T (pt) 2003-11-20 2018-02-26 Novo Nordisk As Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
EP2494983B1 (en) 2004-11-12 2019-04-24 Novo Nordisk A/S Stable formulations of glp-1
BRPI0518761A2 (pt) 2004-12-02 2008-12-09 Domantis Ltd fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
WO2007061434A2 (en) * 2005-11-10 2007-05-31 Nastech Pharmaceutical Company Inc. A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
EP1965828A2 (en) * 2005-12-02 2008-09-10 Nastech Pharmaceutical Company Inc. Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide
KR20100132535A (ko) 2008-03-31 2010-12-17 글락소 그룹 리미티드 약물 융합체 및 컨주게이트
PE20120514A1 (es) 2009-03-27 2012-05-14 Glaxo Group Ltd Fusiones y conjugados de agentes insulinotropicos o farmacos incretina con anticuerpos dab anti-albumina serica
SG10201406063XA (en) 2009-09-30 2014-11-27 Glaxo Group Ltd Drug fusions and conjugates with extended half life
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
CN104244981A (zh) 2011-12-09 2014-12-24 诺和诺德A/S Glp-1激动剂
GB201308753D0 (en) * 2013-05-15 2013-06-26 Stichting Nl Kanker Inst Compounds and their use in therapy
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
PE20221575A1 (es) 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
WO1990009385A1 (en) * 1989-02-17 1990-08-23 The Liposome Company, Inc. Lipid excipient for nasal delivery and topical application
GB8918879D0 (en) * 1989-08-18 1989-09-27 Danbiosyst Uk Pharmaceutical compositions
ATE164852T1 (de) * 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung

Also Published As

Publication number Publication date
KR950700754A (ko) 1995-02-20
AU3888793A (en) 1993-10-21
WO1993018785A1 (en) 1993-09-30
JPH07504669A (ja) 1995-05-25
EP0631504A1 (en) 1995-01-04

Similar Documents

Publication Publication Date Title
DE59303358D1 (de) Quaterrylentetracarbonsäureimide
DE59306810D1 (de) Gutbettwalzenmühle
DE59302851D1 (de) Sportschuh
BR9305745A (pt) Quebra-luz
DE59301902D1 (de) Kassenlade
DE59305364D1 (de) Rotornut
BR9301712A (pt) Aplainador
DE59304139D1 (de) Polyanile
FIU920454U0 (fi) Raeddningsanordning
ATA227792A (de) Sportschuh
DE59301762D1 (de) Chlorethylsulfonylbenzaldehyde
DK59092D0 (da) Praeparat
SK964U (sk) Komplexný fytogeriatrický preparát
DE59206388D1 (de) Kabeleckkanal
BR7200318U (pt) Cabide sanfonado
ATA27393A (de) Alpinski
BR9202723A (pt) Pipex
BR9203234A (pt) Sofa-mesa
FIU920178U0 (fi) Fyllning foer WC-spolcistern
ATA58493A (de) Lochstein
BR7201352U (pt) Luninaria
FIU920437U0 (fi) Skraptramsportoer
BR9200554A (pt) Lixoduto
BR7200879U (pt) Cocho saleiro biazi
BR9204368A (pt) Auto-coletor

Legal Events

Date Code Title Description
ATS Application withdrawn